Skip to main content
Publications
Kummar S, Shen L, Martinus van Tilburg C, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C, Norenberg R, Fellous MM, Brega N, Xu R, Laetsch TW, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Poster presented at the 2022 ASCO Annual Meeting; June 3, 2022. Chicago, IL. [abstract] Am J Clin Oncol. 2022 Jun; 40(16_suppl):6563. doi: 10.1200/JCO.2022.40.16_suppl.6563
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230
Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. HIFMECH Study Group. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost. 2003;1(11):2322-9.